SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 784.97+0.2%Dec 26 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DewDiligence_on_SI who wrote (3258)3/23/2021 4:01:45 PM
From: A.J. Mullen  Read Replies (1) of 3559
 
REGN needs to develop a subcutaneous formulation.
How difficult is that? Presumably it's easier at lower doses. Might the threshold of possibility lie between 300 and 1200mg?

Pfizer's starting a Phase I trial of a pill to block viral replication in people with the first symptoms of Covid, bloomberg.com. It should be much quicker for REGN to gain approval for modified delivery.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News